TriangleNCT01321554 · CITED IN SOURCE DOCUMENTS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2023-06-22
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion criteria: 1. Histologically or cytologically confirmed diagnosis of one of the following DTC subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC). 2. Measurable disease according to (RECIST 1.1) and confirmed by central radiographic review. 3. 131 I-refractory/resistant disease. 4. Evidence of disease progression within 12 months prior to signing informed consent (+1 month screening window). 5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular endothelial growth-factor receptors (VEGFR) targeted therapy. 6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the protocol. Exclusion criteria: 1. Anaplastic or medullary carcinoma of the thyroid 2. 2 or more prior VEGF/ VEGFR-targeted therapies 3. Received any anticancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug. Inclusion criteria for OOL Lenvatinib Treatment Period : Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period if the met the following criteria: 1. Placebo-treated participants in the Randomization Phase who had progressive disease (PD) confirmed by IIR, and who requested treatment with lenvatinib. 2. Participants who continued to satisfy specified inclusion and exclusion criteria as presented in the study protocol. 3. Participants with maximum interval between the day of confirmation of PD by IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3 months. 4. No systemic anticancer treatment during the interval between the day of confirmation of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
- intervention Names
- Drug: Lenvatinib
- label
- Lenvatinib (Randomization Phase)
- type
- EXPERIMENTAL
- description
- Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
- intervention Names
- Drug: Placebo
- label
- Placebo (Randomization Phase)
- type
- PLACEBO_COMPARATOR
- description
- Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
- intervention Names
- Drug: Lenvatinib
- label
- Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)
- type
- EXPERIMENTAL
- description
- Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
- intervention Names
- Drug: Lenvatinib
- label
- Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Lenvatinib (Randomization Phase)
- Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)
- description
- Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
- name
- Lenvatinib
- other Names
- Lenvatinib (Lenvima, E7080)
- type
- DRUG
- arm Group Labels
- Placebo (Randomization Phase)
- description
- Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
- name
- Placebo
- type
- DRUG
- arm Group Labels
- Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)
- description
- Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity. The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.
- name
- Lenvatinib
- other Names
- Lenvatinib (Lenvima, E7080)
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- TRIPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 392
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded IIR using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.
- measure
- Progression Free Survival (PFS)
- time Frame
- Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
- secondary Outcomes
- description
- ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.
- measure
- Overall Response Rate (ORR)
- time Frame
- Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
- description
- Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.
- measure
- Overall Survival (OS)
- time Frame
- Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
- measure
- Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve
- time Frame
- Cycle 1 Days 1 and 15: 0-10 hours postdose; Cycle 2 Day 1: 0-12 hour postdose
Full study description
- brief Summary
- This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).
- detailed Description
- Randomization Phase: Participants will receive blinded study drug (lenvatinib/placebo) in 2:1 ratio until documentation of disease progression (confirmed by independent imaging review), development of unacceptable toxicity, or withdrawal of consent. After having completed the primary analysis, subjects treated with lenvatinib who have not experienced disease progression may request to continue open label lenvatinib at the same dose, according to the clinical judgment of the investigator. Participants who discontinue treatment for any reason other than disease progression will be followed in the Randomization Phase until disease progression or start of another anticancer treatment; these participants then enter the Extension Phase for survival follow-up. Extension Phase: Participants in the placebo arm who have disease progression confirmed by IIR could request to enter the OOL Lenvatinib Treatment Period and receive lenvatinib treatment. Participants will receive lenvatinib treatment until disease progression (investigator's assessment), development of intolerable toxicity, or withdrawal of consent. Participants who had disease progression during the Randomization Phase and did not enter the OOL Lenvatinib Treatment Period and all participants who discontinued lenvatinib treatment in the OOL Lenvatinib Treatment Period will enter the follow-up period. Participants will be followed for survival, and all anticancer treatments will be recorded until the time of death.
Source references
- references
- citation
- Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021 Aug;31(8):1226-1234. doi: 10.1089/thy.2020.0779. Epub 2021 Apr 29.
- pmid
- 33637020
- type
- DERIVED
- citation
- Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, Dutcus CE, Suzuki T, Ren M, Wirth LJ. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2021 Apr;147:51-57. doi: 10.1016/j.ejca.2020.12.032. Epub 2021 Feb 19.
- pmid
- 33611104
- type
- DERIVED
- citation
- Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019 Jan;106:61-68. doi: 10.1016/j.ejca.2018.10.002. Epub 2018 Nov 22.
- pmid
- 30471649
- type
- DERIVED
- citation
- Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 Apr;75:213-221. doi: 10.1016/j.ejca.2017.01.013. Epub 2017 Feb 24.
- pmid
- 28237867
- type
- DERIVED
- citation
- Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109. doi: 10.1210/jc.2015-3989. Epub 2016 Aug 22.
- pmid
- 27548104
- type
- DERIVED
- citation
- Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec;106(12):1714-21. doi: 10.1111/cas.12826. Epub 2015 Nov 2.
- pmid
- 26426092
- type
- DERIVED
- citation
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
- pmid
- 25671254
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-2a9771add8bfbd32636b
- requested nct id
- NCT01321554
- primary nct id
- NCT01321554
- source kind
- fda_spl_label
- source record id
- e2339aa3-c753-4269-9c59-1d6528a00f0c
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 029f1f5fa72d803b50f22243c69b79deffc10dd25dc2880ab763501105c99f68
- payload
- application numbers
- NDA206947
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-2a9771add8bfbd32636b
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01321554
- occurrences
- context exact
- Survival in Study 309 (pMMR or not MSI-H) 14.1 Differentiated Thyroid C ancer A multicenter, randomized (2:1), double-blind, placebo-controlled study (SELECT; NCT01321554) was conducted in 392 patients with locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer and radiographic evidence of di
- end
- 551
- exact text
- NCT01321554
- start
- 540
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/47/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- e2339aa3-c753-4269-9c59-1d6528a00f0c
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- d501fa0f9dca778737cacc8a0261e6e35057b46e8a8be38ebd95df76b61c00d9
- spl effective time
- 20260630
- spl set id
- f4bedd21-efde-44c6-9d9c-b48b78d7ed1e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-67a964a03628ef1a57ee
- requested nct id
- NCT01321554
- primary nct id
- NCT01321554
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 39acd14f241a393ba0bdf760fdf53704855b8c2472619c8b5dbdb097f1c00b15
- payload sha256
- f20ec0ac031e32e48cba96c7f0ecb905b092d91d32bb41f845a10dcf22b607b3
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-67a964a03628ef1a57ee
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01321554
- occurrences
- context exact
- :</p> <div class="pdq-content-list"><ol id="_1089"><li> A phase III, randomized, double-blind, placebo-controlled study (<a href="/clinicaltrials/NCT01321554">SELECT</a> [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[<a href="#cit/s
- end
- 109310
- exact text
- NCT01321554
- start
- 109299
- context exact
- class="pdq-content-list"><ol id="_1089"><li> A phase III, randomized, double-blind, placebo-controlled study (<a href="/clinicaltrials/NCT01321554">SELECT</a> [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[<a href="#cit/section_5.22">22</a>] In t
- end
- 109335
- exact text
- NCT01321554
- start
- 109324
- context exact
- ):</p> <div class="pdq-content-list"><ol id="_1020"><li>A phase III, randomized, double-blind, placebo-controlled study (<a href="/clinicaltrials/NCT01321554">SELECT</a> [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[<a href="#cit/s
- end
- 120926
- exact text
- NCT01321554
- start
- 120915
- context exact
- class="pdq-content-list"><ol id="_1020"><li>A phase III, randomized, double-blind, placebo-controlled study (<a href="/clinicaltrials/NCT01321554">SELECT</a> [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[<a href="#cit/section_5.22">22</a>] In t
- end
- 120951
- exact text
- NCT01321554
- start
- 120940
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/c01da54cc166a027c3.html
- source file sha256
- 39acd14f241a393ba0bdf760fdf53704855b8c2472619c8b5dbdb097f1c00b15
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:22:23.753084+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 38a05bdedb5998c61245bfd87d992e90aaf1624d874d669ee39e1ee068f1b4e7
- source title
- Thyroid Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 9, 2025
- datetime
- 2025-05-09T12:00:00Z
- display
- May 9, 2025
Preserved source evidence · Not medical advice